Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and dapagliflozin in type 2 diabetes patients with SIDD or SIRD characteristics
2020-000913-33Phase 2Completed
- Sponsor
- University of Gothenburg
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of semaglutide and dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Gothenburg. Primary endpoint: Change in HbA1c from baseline. Started Mar 2020; status: completed.
02
Drugs
semaglutidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-000913-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000913-33.